KLK3 and prostate cancer: Patients with a past history or investigations suggesting bladder or prostate cancer, PSA concentration >2 ng ml–1, urine NMP22 concentration >7 U ml–1, urolithiasis or visible haematuria and incomplete imaging were excluded, leaving 28 men in the control cohort.